title: Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients.
abstract: OBJECTIVE
  The objective of this work was to study characteristics and clinical treatment patterns of bipolar disorder (BD) patients admitted to hospital and treated with quetiapine (immediate-release [IR] or extended-release [XR] formulations).
  
  
  METHODS
  BD patients admitted to hospital and prescribed quetiapine IR were followed by linking two Swedish nationwide registries; the hospitalization and drug dispense registries [ClinicalTrials.gov identifier: NCT01455961]. The study period was from 1 January 2008, to end of 31 December 2011. Data was primarily analysed using descriptive methods.
  
  
  RESULTS
  Quetiapine IR was used in 1761 patients of whom 1303 subsequently switched to XR (switch XR) and 458 remained on IR (continuous IR). At baseline, Switch XR patients were younger (-3.3 years), more frequently employed (+7.1%), had higher prevalence of single depressive episodes (+6.7%) and anxiety disorders (+5.8%), lower mean daily IR dose (-19.3%) and fewer medications for somatic disorders (-7.5%) than continuous IR patients. During follow up, the number of concomitant psychiatric medications was lower in switch XR patients (-6%) and higher in continuous IR patients (+6%). Mean daily quetiapine dose was 21% higher in switch XR versus continuous IR patients. Prescriptions of lower quetiapine dosages calculated below 50 mg per day in the XR switch and IR continuous groups were seen in 8% versus 10% of the patients, respectively.
  
  
  CONCLUSIONS
  Differential use of quetiapine XR and IR in bipolar disorder patients with different and important characteristics was demonstrated. Patients who were switched to quetiapine XR had a higher psychiatric disease burden, were younger and had a higher degree of employment. These differences demonstrate the heterogeneity among bipolar disorder patients and indicate the need in clinical practice for individualized treatment to reduce the risk for both patient and society related losses.
authors: Department of Emergency Psychiatry, St Görans Hospital, SE-112 81, Department of Clinical Neuroscience, Centre for Psychiatric Research and Education, Karolinska Institutet, Stockholm, Sweden.
authors: Andreas
authors: A
authors: Carlborg
authors: Statisticon AB, Uppsala, Sweden.
authors: Marcus
authors: M
authors: Thuresson
authors: AstraZeneca NordicBaltic, Södertälje, Sweden.
authors: Lena
authors: L
authors: Ferntoft
authors: AstraZeneca NordicBaltic, Södertälje, Sweden.
authors: Johan
authors: J
authors: Bodegard
keywords: bipolar disorder; patient characteristics; pharmacotherapy; quetiapine XR/IR; real-life clinical practise; switching medication
references: Bipolar Disord. 2007 Jun;9(4):413-25
references: 17547587
references: Int J Neuropsychopharmacol. 2011 Nov;14 (10 ):1357-66
references: 21477416
references: Bipolar Disord. 2013 Feb;15(1):1-44
references: 23237061
references: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204
references: 18948162
references: Clin Pract Epidemiol Ment Health. 2009 Jan 23;5:3
references: 19166608
references: Bipolar Disord. 2015 Feb;17(1):76-85
references: 25056132
references: Adv Ther. 2010 Nov;27(11):774-84
references: 20835785
references: Bipolar Disord. 2007 Aug;9(5):531-5
references: 17680925
references: BMC Psychiatry. 2013 May 29;13:153
references: 23714262
references: Curr Med Res Opin. 2008 Aug;24(8):2271-82
references: 18588748
references: Neuropsychiatr Dis Treat. 2013;9:197-204
references: 23431086
references: J Clin Psychiatry. 2010 Sep;71(9):1176-86; quiz 1252-3
references: 20923622
references: Lancet. 2007 Sep 8;370(9590):859-77
references: 17804063
references: Clin Ther. 2009 Mar;31(3):492-502
references: 19393840
references: BMC Psychiatry. 2012 Aug 02;12:99
references: 22856540
references: Int Clin Psychopharmacol. 2012 Nov;27(6):310-3
references: 22990141
references: Ann Clin Psychiatry. 2011 Feb;23(1):40-7
references: 21318195
references: BMC Psychiatry. 2012 Sep 21;12:153
references: 22998655
references: J Clin Psychiatry. 2006 Mar;67(3):355-62
references: 16649820
references: PLoS One. 2013 Jun 24;8(6):e67133
references: 23826212
references: Psychiatry (Edgmont). 2007 Nov;4(11):34-50
references: 20428302
references: J Affect Disord. 2002 Apr;68(2-3):167-81
references: 12063145
references: Ther Adv Psychopharmacol. 2011 Oct;1(5):153-62
references: 23983940
references: Soc Psychiatry Psychiatr Epidemiol. 2013 Oct;48(10):1601-10
references: 23754681
references: Arch Gen Psychiatry. 2000 Jun;57(6):553-9
references: 10839333
references: Hum Psychopharmacol. 2012 Sep;27(5):492-8
references: 22996616
references: BMJ Open. 2013 Apr 18;3(4):null
references: 23604348
references: Patient Prefer Adherence. 2013;7:89-94
references: 23378745
references: J Clin Psychopharmacol. 2006 Dec;26(6):600-9
references: 17110817
references: Am Fam Physician. 2012 Mar 1;85(5):483-93
references: 22534227
references: J Clin Psychiatry. 2007 Jun;68(6):899-907
references: 17592915
references: BMJ Open. 2012 Jul 02;2(4):null
references: 22761282
references: Arch Gen Psychiatry. 2007 May;64(5):543-52
references: 17485606
references: Schizophr Bull. 2009 Sep;35(5):931-6
references: 18385207
references: Br J Psychiatry. 2011 Dec;199(6):453-8
references: 21593516
references: J Psychopharmacol. 2009 Jun;23(4):346-88
references: 19329543
references: Arch Gen Psychiatry. 2011 Mar;68(3):241-51
references: 21383262
references: J Clin Psychiatry. 2008 May;69(5):769-82
references: 18452345
references: J Affect Disord. 2010 Feb;121(1-2):106-15
references: 19903574
references: J Clin Psychiatry. 2002;63 Suppl 13:5-11
references: 12562141
references: Ther Adv Psychopharmacol. 2012 Dec;2(6):217-26
references: 23983980
references: Med J Aust. 2010 Aug 16;193(4 Suppl):S24-30
references: 20712557
references: Eur J Epidemiol. 2009;24(11):659-67
references: 19504049
references: Clin Ther. 2013 Dec;35(12):1923-32
references: 24275622